Jiyeon Yoon

CONTACT

Lead Sponsor

Hanmi Pharmaceutical Company Limited

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histologically and/or cytologically confirmed advanced or metastatic solid tumor who have failed/are intolerant to standard therapy.
•Patients for dose-escalation part must have evaluable or measurable disease at baseline and the patients for randomized dose-ranging and dose-expansion part must have at least one measurable lesion at baseline by CT or MRI per Response Evaluation Criteria in Solid Tumor (RECIST v1.1).
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
•Life expectancy ≥ 3 months before starting HM97662.
•Adequate renal function.
•Adequate hematologic function.
•Adequate liver function.
•Males or females aged ≥ 18 years (or country's legal age of majority if the legal age was \> 18 years) at the time of informed consent.
•For Dose-Ranging Part, documentation of an alteration in at least one of the genes of the SWI/SNF complex in tumor tissue (archival or newly obtained).

•Prior exposure to valemetostat or other EZH1/2 dual inhibitor.
•Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms.
•Patients currently taking medications that are known strong CYP3A inhibitors and strong or moderate CYP3A inducers.
•Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 per CTCAE version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.
•Major surgery within 4 weeks before the first dose of study drug treatment in Cycle 1.
•Females who are pregnant or breastfeeding.
•Patients who have undergone an organ transplant.

Related studies

NCT06248411 · Advanced or Metastatic Solid Tumors

NCT06716138 · Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

NCT06307795 · Locally Advanced or Metastatic Solid Tumors

NCT05753722 · Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, and more

NCT05581004 · Locally Advanced or Metastatic Solid Tumors, NSCLC, and more

Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors